Acne treatment Differin Gel approved for OTC use

Acne treatment Differin Gel approved for OTC use

Updated:
© Stockbyte / Thinkstock © Stockbyte / Thinkstock

(HealthDay News) -- The once-daily acne treatment Differin Gel 0.1% (adapalene) has been approved for over-the counter use among people 12 and older, the U.S. Food and Drug Administration said.

It's the first among a class of drugs called retinoids to be made available over the counter to treat acne. The drug's active ingredient is the first new OTC acne treatment approved since the 1980s, the FDA said in a news release.

Differin Gel 0.1% was first approved in 1996 as a prescription drug.

Acne affects some 50 million people in the United States, mostly teens and young adults, the FDA said. Clusters of pimples most often form on the face, neck, back, chest and shoulders.

The agency warned that women who are pregnant, planning to become pregnant or breast feeding should get their doctor's approval before using the product. While no specific issues with pregnant or breast-feeding women using Differin Gel have been identified, some retinoid drugs have been shown to cause birth defects, the FDA said.

Differin Gel 0.1% is distributed by Galderma Laboratories, based in Fort Worth, Tex.

More information

Visit Medline Plus to learn more about this drug.

Copyright © 2016 HealthDay. All rights reserved.

*DISCLAIMER*: The information contained in or provided through this site section is intended for general consumer understanding and education only and is not intended to be and is not a substitute for professional advice. Use of this site section and any information contained on or provided through this site section is at your own risk and any information contained on or provided through this site section is provided on an "as is" basis without any representations or warranties.
Powered by Frankly
All content © Copyright 2000 - 2019 WNCONTENT. All Rights Reserved.
For more information on this site, please read our Privacy Policy, and Terms of Service, and Ad Choices.